{"id":"exenatide-once-weekly-eqw","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Nausea"},{"rate":"5–15","effect":"Vomiting"},{"rate":"10–20","effect":"Diarrhea"},{"rate":"5–10","effect":"Hypoglycemia"},{"rate":"5–10","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Exenatide mimics glucagon-like peptide-1 (GLP-1), an incretin hormone that enhances glucose-dependent insulin secretion from pancreatic beta cells. It also inhibits glucagon secretion when blood glucose is elevated and delays gastric emptying, which collectively reduce postprandial blood glucose excursions. The once-weekly formulation (EQW) uses extended-release microsphere technology to provide sustained drug delivery over seven days.","oneSentence":"Exenatide is a GLP-1 receptor agonist that stimulates insulin secretion in response to elevated blood glucose and slows gastric emptying to reduce postprandial glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:35.003Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01554618","phase":"PHASE3","title":"Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-12-02","conditions":"Children and Adolescent With Type 2 Diabetes","enrollment":84},{"nctId":"NCT02635386","phase":"PHASE3","title":"EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Woman's","startDate":"2016-03-22","conditions":"Polycystic Ovary Syndrome, Obesity","enrollment":119},{"nctId":"NCT04029272","phase":"PHASE4","title":"Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-07-20","conditions":"Polycystic Ovary Syndrome","enrollment":80},{"nctId":"NCT02843399","phase":"","title":"Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-08-15","conditions":"Diabetes Mellitus Type 2","enrollment":15498}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["• Bydureon","• Long acting glucagon like peptide 1 (GLP1) agonist"],"phase":"phase_3","status":"active","brandName":"Exenatide once weekly (EQW )","genericName":"Exenatide once weekly (EQW )","companyName":"Woman's","companyId":"woman-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Exenatide is a GLP-1 receptor agonist that stimulates insulin secretion in response to elevated blood glucose and slows gastric emptying to reduce postprandial glucose levels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}